HALLE (SAALE), Germany, 06 March 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is scheduled to attend and present at the following conferences:
15 March 2017, Sofitel Legend The Grand Amsterdam, Amsterdam, The Netherlands
Dr Hendrik Liebers, CFO, to present on Wednesday, March 15, 2017 at 4:00 pm CET in the St. Cecilia Chamber
20 – 22 March 2017, CCIB Convention Centre, Barcelona, Spain
Dr Konrad Glund, CEO, to present on Tuesday, March 21, 2017 at 4:15 pm CET in Room 118 on level 1
(3) Oppenheimer Annual Healthcare Conference
21 – 22 March 2017, The Westin New York Grand Central, New York City, USA
Dr Hendrik Liebers, CFO, to present on Tuesday, March 21, 2017 at 2:45 pm EST in the Track 61 Room
(4) Neuroscience Biopartnering and Investor Forum
27 March 2017, New York Academy of Sciences, New York City, USA
Dr Hendrik Liebers, CFO, to present Monday, March 27, 2017 at 11:25 EST in Track A and join the panel Advances in Alzheimer’s Disease on Monday, March 27, 2017 at 10:25 am EST
(5) World Neuroscience Innovation Forum
27 March 2017, Francis Crick Institute, London, UK
Dr Konrad Glund, CEO, to attend the conference
29 March – 2 April 2017, Austria Centre, Vienna, Austria
Dr Konrad Glund, CEO and Dr Inge Lues, CDO, to attend the conference
For more information, please contact:
Dr Konrad Glund, CEO
Conor Griffin, Alexia Faure, Alexander Protsenko
Tel: +44 (0) 20 7862 6381
The Trout Group
Tricia Truehart, Kelly Mueller
Tel: +1 (646) 378-2953
MC Services AG
Anne Hennecke, Caroline Bergmann
Tel: +49 (0) 211 529 252 20
Notes to Editors:
About Probiodrug AG
Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.
Probiodrug’s lead product candidate, PQ912, is a highly specific and potent inhibitor of Glutaminyl Cyclase (QC), which has shown therapeutic effects in Alzheimer’s animal models. PQ912 is currently in a Phase 2a study, the SAPHIR trial. In a preceding Phase 1 study with healthy young and elderly volunteers, PQ912 has shown to be safe and well tolerated and also revealed high QC-inhibition.
About Alzheimer’s disease
Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 47 million people live with dementia worldwide, and this number is projected to treble to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. Alzheimer’s has an estimated, global societal cost of US$ 818 billion, and it will become a trillion dollar disease by 2018. (World Alzheimer Report 2016).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.